← Eichor
Study identifier: NCT06948136 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Acute Effects of THC in Older Adult

Condition: Age-related Cognitive Decline  ·  Sponsor: Yale University

PhasePhase 1
Planned participants60
Who can joinAll sexes, 21 Years to no upper limit
Healthy volunteersYes

About this study

The primary objective of this study is to determine if increasing age confers greater vulnerability to the acute A) cognitive (e.g., memory, attention, psychomotor function), B) subjective (e.g., anxiogenic and rewarding effects), and C) cardiovascular (heart rate and blood pressure), effects of THC in adults \> 21 years old. The secondary aims of the study are to explore age-related acute effects of THC on electrophysiological indices of information processing (e.g., auditory steady-state response (ASSR), oddball paradigm \[P300\], and resting state cortical noise) and to determine age-related differences in the metabolism of THC.

This description comes directly from the study's public registry record.

Talk to the study team

Deepak C D'Souza  ·  203-932-5711  ·  deepak.douza@yale.edu

Ashley Schnakenberg Martin, PhD  ·  ashley.martin@yale.edu

Always discuss trial participation with your own doctor first.

Locations (1)

VA Connecticut Healthcare SystemWest Haven, Connecticut, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06948136